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Abstract
Background: The European Union (EU) aims to optimize patient protection and efficiency of health-care research
by harmonizing procedures across Member States. Nonetheless, further improvements are required to increase
multicenter research efficiency. We investigated IRB procedures in a large prospective European multicenter study
on traumatic brain injury (TBI), aiming to inform and stimulate initiatives to improve efficiency.
Methods: We reviewed relevant documents regarding IRB submission and IRB approval from European
neurotrauma centers participating in the Collaborative European NeuroTrauma Effectiveness Research in Traumatic
Brain Injury (CENTER-TBI). Documents included detailed information on IRB procedures and the duration from IRB
submission until approval(s). They were translated and analyzed to determine the level of harmonization of IRB
procedures within Europe.
Results: From 18 countries, 66 centers provided the requested documents. The primary IRB review was conducted
centrally (N = 11, 61%) or locally (N = 7, 39%) and primary IRB approval was obtained after one (N = 8, 44%), two
(N = 6, 33%) or three (N = 4, 23%) review rounds with a median duration of respectively 50 and 98 days until
primary IRB approval. Additional IRB approval was required in 55% of countries and could increase duration to 535
days. Total duration from submission until required IRB approval was obtained was 114 days (IQR 75–224) and
appeared to be shorter after submission to local IRBs compared to central IRBs (50 vs. 138 days, p = 0.0074).
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Conclusion: We found variation in IRB procedures between and within European countries. There were differences
in submission and approval requirements, number of review rounds and total duration. Research collaborations
could benefit from the implementation of more uniform legislation and regulation while acknowledging local
cultural habits and moral values between countries.
Keywords: Research ethic committees, European Union, Health-care research, CENTER-TBI, Harmonization
Background
A Research Ethics Committee or Institutional Review
Board (collectively referred to as IRB in the remainder of
this manuscript) is appointed to review research proto-
cols to ensure their compliance with ethical standards
and national laws. IRBs have an essential role in (clin-
ical) research to protect the dignity, fundamental rights,
safety, and well-being of research participants and their
formal approval is compulsory before a clinical study
can start [1]. Although several international models exist
to improve the harmonization of ethical principles, the
functioning of IRBs are subject to national legislation
and regulation, which refine their structure and function
to better serve local needs and cultural preferences [2,
3]. Approval of research protocols submitted to IRBs is
subject to these differences, which may complicate the
conduct of international research.
Managing variations in IRB procedures is important
because of the increasing number of research initiatives
which involve multiple European Union (EU) Member
States [4–6]. Variation could be improved by
harmonization of European law, which is the process of
creating uniformity in laws, regulations and practices
between countries. Regarding research and IRB proce-
dures, lack of procedural harmonization ‘leads to a com-
plex and uncertain framework for ethical review and for
participant information consent, resulting in numerous
inefficiencies in observational studies’ [7]. Greater pro-
cedural harmonization is generally considered desirable,
because it could improve quality and efficiency of
healthcare research by decreasing costs, increasing statis-
tical validity, [8–10] optimizing data management, [10]
allowing choice of relevant and generalizable outcome
variables, [9] promoting uniform product safety regula-
tions [8] and minimizing waste of resources due to inef-
ficiencies [8].
Although most IRBs have websites that describe the
local submission process and provide access to submis-
sion guidelines and forms, up to date systematic
information on IRB procedures and their level of
harmonization in European health-care research is
scarce. We are aware of only one previous meta-analysis
on IRB procedures across European countries from 2005
to 2007 that was also related to research involving
acutely mentally incapacitated individuals [6]. The
Collaborative European Neurotrauma Effectiveness Re-
search in Traumatic Brain Injury (CENTER-TBI) study
is a large observational study conducted in many coun-
tries across Europe that provides a unique opportunity
to assess European IRB policies and procedures [11].
This study aims to improve the efficiency of future re-
search initiatives by quantifying the differences in IRB
procedures through analyzing the procedural details,
problems and challenges that researchers encountered in
obtaining IRB approval for the general research protocol
of the CENTER-TBI study.
Methods
Study setting
The Collaborative European NeuroTrauma Effectiveness
Research in Traumatic Brain Injury (CENTER-TBI,
www.center-tbi.eu) Core study is a prospective observa-
tional study on traumatic brain injury (TBI), which was
conducted between December 2014 and December 2017
in 63 neurotrauma centers across Europe and Israel [11,
12]. The study included patients with TBI of all
severities, and aims to improve characterization of TBI,
in order to facilitate the development of precision
medicine approaches and to identify best practices by
using a comparative effectiveness research (CER)
approach [11–14]. In the context of the project high-
quality Personal Health related Data (PHD) were
collected with repositories for neuro-imaging, DNA, and
serum biomarkers. Prior to the study start and collection
of clinical data, a uniform CENTER-TBI research proto-
col including all relevant documents was sent to all re-
sponsible IRBs to ensure its legal, ethical and statistical
soundness and to obtain IRB approval.
A total of 68 centers from 19 countries initially sub-
mitted applications for IRB approval. Because this article
focuses on IRB approval in Europe, two centers from
Israel were excluded from our analysis. The 66 center
that participated in this present study are from Austria
(N = 2), Belgium (N = 5), Denmark (N = 2), Finland (N =
2), France (N = 7), Germany (N = 4), Hungary (N = 3),
Italy (N = 8), Latvia (N = 3), Lithuania (N = 2), the
Netherlands (N = 7), Norway (N = 3), Romania (N = 1),
Serbia (N = 1), Spain (N = 4), Sweden (N = 2),
Switzerland (N = 1), and the United Kingdom (UK),
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(N = 9). Sixty-one European centers were initiated and
actively enrolled patients in the study.
Data collection and administration
All IRB submission documents, communication records
and approval documents were collated per center by the
Contract Research Organization, ICON plc (ICON), dir-
ectly after final approval of IRBs [15]. ICON is a global
company operating in the healthcare industry that was
responsible for the clinical monitoring of CENTER-TBI
data. The received IRB documents were obtained in 15
different languages (Danish, Dutch, English, Finnish,
French, German, Hungarian, Italian, Latvian, Lithuanian,
Norwegian, Romanian, Serbian, Spanish, and Swedish)
and were partly translated before analysis. The authors
contacted the principle investigators to obtain additional
information to minimize the amount of unclear or miss-
ing data. Identifiable information was deleted to protect
the privacy of stakeholders. This resulted in a final set of
documents, that was analyzed for this study.
Analyses
We assessed the IRB review procedures by using the
final set of documents and aimed to answer the follow-
ing research questions in order to evaluate differences in
obtaining IRB approval (1) Was the study considered to
be observational or interventional? (2) Was the research
protocol to be submitted to a central IRB or local IRB
for primary IRB review and primary IRB approval? (3)
Was additional IRB review required after primary IRB
approval had already been obtained? If yes, to what ex-
tent? (4) How many review rounds were conducted be-
fore primary IRB approval was obtained? What were the
reasons? (5) What was the time between protocol sub-
mission and obtaining the required IRB approval to start
the study? The use of ‘primary’ in this context should be
interpreted as first in an order and ‘additional’ as second
in an order, without including a statement on
importance.
To elaborate on the fifth question, we reconstructed
six timeframes regarding the primary IRB review proced-
ure: (1) time between protocol submission and primary
IRB approval or first IRB reaction, (2) time between first
IRB reaction and first reaction of researcher, (3) time be-
tween first reaction of researcher and primary IRB ap-
proval or second IRB reaction, (4) time between second
IRB reaction and second reaction researcher, (5) time
between second reaction researcher and primary IRB ap-
proval, and (6) total time between protocol submission
and primary IRB approval. The existence of these time-
frames naturally depended on the actual procedure. Data
on any additional IRB review focused only on the
duration of this particular review until the required IRB
approval was obtained.
In order to assess regional variation, countries were
grouped into six regions based on the United Nation
geo-scheme: Baltic States (Latvia, and Lithuania), Eastern
Europe (Hungary, Romania, and Serbia), Northern
Europe (Denmark, Finland, Norway, and Sweden),
Southern Europe (Italy, and Spain), the United Kingdom
(UK), and Western Europe (Austria, Belgium, France,
Germany, the Netherlands, Switzerland) [16]. Incom-
plete data was marked ‘Missing’ (M) and all timeframes
were reported in days.
To determine significant differences between the time
from submission till approval of the research protocol
between primary local IRBs and primary central IRBs,
we performed a Mann-Whitney U test (continuous).
Analyses were performed using R version 3.6.0. Finally, a
descriptive analysis of questions, comments and answers
from both IRB and researcher during the IRB review
procedure was performed to summarize the problems
and challenges that researchers encountered in obtaining
IRB approval. IRB reactions were categorized and re-
ported by their appearance: (1) Procedure, (2) Blood col-
lection and biomarkers, (3) MRI, (4) Privacy and data
security, (5) Other.
Results
A total of 66 neurotrauma centers from 18 countries
were included in this analysis. Most centers were located
in Western Europe (N = 26, 39%) and least in Eastern
Europe (N = 5, 8%) and the Baltic States (N = 5, 8%).
Most participating centers were from the UK (N = 9),
followed by Italy (N = 8), The Netherlands and France
(N = 7) (Table 1). In all countries the local principal in-
vestigators were responsible to submit the general
CENTER-TBI research protocol for IRB review and IRB
approval.
Observational or interventional
The majority of countries (N = 14, 78%) considered the
study to be observational, while others judged it to be
observational with diagnostic interventions (The
Netherlands), interventional (France, Hungary) and ob-
servational and interventional (Serbia) (Table 1).
Primary central or primary local IRB review
Primary IRB review started directly after protocol sub-
mission and was considered ‘central’ when submitted to
a central institution or an institution that was part of a
national network (N = 11, 61%). There were three op-
tions: (1) Primary central IRB approval had a national
impact and applied to all participating centers within a
country, without the need for additional IRB review
(N = 5; Denmark, Finland, France, Norway, Sweden). (2)
Primary central IRB approval only allowed study start in
the research centers associated with the approving IRB.
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Other participating centers in the country required ap-
proval after an additional extensive local IRB review.
This involved the re-evaluation of the entire protocol
and applicable ethics (N = 4; Belgium, Germany,
Hungary, Italy). (3) Primary central IRB approval only
allowed study start in the research centers associated
with the approving IRB. Other participating centers re-
quired additional approval after marginal local IRB re-
view, mainly assessing local feasibility (N = 2; UK, The
Netherlands) (Fig. 1).
Primary IRB review was considered ‘local’ when the
protocol was submitted to an independent ‘local’ IRB.
Obtained primary local IRB approvals only applied to
the associated research centers and allowed study start
without any additional requirements (N = 7; Austria,
Switzerland, Spain, Lithuania, Latvia, Romania, Serbia).
Primary local IRB review could be performed simultan-
eously in each independent IRB (Fig. 1).
For every protocol submission, there were two out-
come options after IRB review: (1) the required (primary
or additional) IRB approval had been obtained and the
study could start, or (2) researchers were asked to an-
swer questions or make protocol changes, which was
followed by an extra IRB review round. This process var-
ied between IRBs and was repeated until the required
IRB approval was eventually obtained. None of the sub-
missions in this study were rejected.
IRB review rounds
Eight countries (44%), including all countries from
Eastern Europe and the Baltic State, obtained primary
IRB approval in the first round after submission, while
six countries (Austria, Belgium, France, Finland, Spain
and UK) required one extra review round and four
countries (Denmark, Germany, Norway and Sweden) re-
quired two extra review rounds (Fig. 2). Extra review
rounds were found in 73% of centers after primary cen-
tral IRB submission and in 20% after primary local IRB
submission.
Several IRBs commented on different aspects of the
protocol: selection criteria (n = 3, 38%), patient/proxy
consent (n = 4, 50%), and information forms (n = 3, 38%).
Also, specific questions were asked on possible non-
standard care factors in particular MRI scans (N = 4),
blood sample collection (N = 4). Four questions were
asked about privacy and data security, mainly related to
the period after study completion. All relevant informa-
tion can be found in the supplementary files.
Duration from protocol submission to IRB approval
The median time from protocol submission until the re-
quired IRB approval was obtained to start the study was
114 days (IQR 75–224). The fastest required IRB ap-
proval was obtained after one day in Serbia and
Romania, whereas the longest time was found in a center
in the UK (535 days). Obtaining central IRB approval
(138 days, IQR: 91–229) took significantly longer (p =
0.0074) than obtaining local IRB approval (50 days, IQR:
29–102) (Table 2).
In Norway and Denmark, the majority of time from
submission to primary central IRB approval was spent
by researchers (67 and 69%, respectively), while in
France (95%) and Hungary (71%) most time was con-
sumed by IRBs. Regarding primary local IRB submis-
sions, researchers only accounted for 12% of time in
Spain and 21% in Austria (Fig. 2).
Additional IRB review rounds after primary central
IRB review were required in 55% of countries. An
additional marginal (feasibility) review had a median







IRB decision on study
type
Baltic States 5
Latvia 3 Locala Observational
Lithuania 2 Local Observational
Eastern Europe 5
Hungary 3 Central Interventional
Romania 1 Local Observational
Serbia 1 Local Observational and
Interventional
Northern Europe 9
Denmark 2 Central Observational
Finland 2 Central Observational
Norway 3 Central Observational
Sweden 2 Central Observational
Southern Europe 12
Italy 8 Central Observational
Spain 4 Local Observational
United Kingdom 9
United Kingdom 9 Centralb Observational
Western Europe 26
Austria 2 Local Observational
Belgium 5 Central Observational
France 7 Central Interventional
Germany 4 Central Observational
Netherlands 7 Central Observational with
diagnostic interventions
Switzerland 1 Local Observational
a Latvia has a local review procedure, but, after approval had been obtained
for the first center, other centers did not require additional approval
b In the UK, the research protocol had to be submitted to an external national
committee that was not associated to the submitting center. After primary
approval by this national committee, all centers (including the submitting
center) required additional IRB approval
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Fig. 1 Flowchart of IRB review and approval processes in the CENTER-TBI study. This figure shows an overview of the different IRB review and
approval processes in the CENTER-TBI study. IRB; Institutional Review Board
Fig. 2 Detailed overview of primary IRB review rounds and duration. This figure provides a detailed overview of the number of primary local and
central IRB review rounds and their duration in days. *The number of review rounds was only reported for the initial center of each country.
**Information on the first review round was missing. ***Only the total number of days was available
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duration of 104 days (IQR: 62–224), whereas an add-
itional extensive IRB review took 189 days (IQR: 140–
270) (Table 3).
Variation between centers within countries was least
in Lithuania (31 to 47 days), Germany (288 to 312 days),
Belgium (131 to 155 days), and Hungary (177 to 204
days), compared to Spain (69 to 349 days), the
Netherlands (27 to 224 days), the UK (58 to 535 days),
and Italy (65 to 288 days) (Table 3).
Discussion
This study shows variation in IRB procedures between
and within European countries, indicating a lack of uni-
form legislation and regulation, or inconsistencies in
how such legislation or regulation were implemented. In
some countries, a primary central IRB approval was suf-
ficient for study initiation, while others required an add-
itional IRB review at the participating site. Also, the
number of review rounds, duration until IRB approval,
and the nature of questions and comments from the
Table 2 Duration of protocol submission until required IRB
approval before study start
Duration (days)a Centers (N) Missing (N)
All centers 114 (75–224) 58 8
Local review 50 (29–102) 10 4
Central review 138 (91–229)b 48 4
- Central (1) 98 (94–114) 16 0
- Central (2) 189 (140–270) 17 3
- Central (3) 104 (62–224) 15 1
Local review: Obtained primary local IRB approvals only applied to the associated
research centers and allowed study start without any additional requirements
Central (1): Primary central IRB approval with national impact, applying to all
center within a country, without the need for additional local IRB review
Central (2): Primary central IRB approval only allowed study start in the
research centers associated with the approving IRB. Other participating centers
required approval after additional extensive local IRB review
Central (3): Primary central IRB approval only allowed study start in the
research centers associated with the approving IRB. Other participating centers
required approval after additional marginal local IRB review
aDuration was reported in median number of days (IQR)
bGroup differences between local and central review were significant (P =
0.0074, Mann-Whitney U)






1 2 3 4 5 6 7 8 9
Denmark Central (1) 114 114
Finland Central (1) 75 75
France Central (1) 98 98 98 98 98 98 98
Norway Central (1) 233 233 233
Sweden Central (1) 83 83
Belgium Central (2) 131 138 141 257 M
Germany Central (2) 288 296 312 M
Hungary Central (2) 177 200 204
Italy Central (2) 65 70 139 141 155 261 273 288
Netherlands Central (3) 27 46 91 209 223 224 M
United Kingdoma Central (3) 58 61 63 84 104 157 229 282 535
Austria Local 52 M
Latvia Local 113 M M
Lithuania Local 31 47
Romania Local 1
Serbia Local 1
Spain Local 69 179 349 M
Switzerland Local 28
Central (1): Primary central IRB approval with national impact, applying to all center within a country, without the need for additional local IRB review to
start study
Central (2): Primary central IRB approval only allowed study start in the research centers associated with the approving IRB. Other participating centers required
approval after additional extensive local IRB review to start study
Central (3): Primary central IRB approval only allowed study start in the research centers associated with the approving IRB. Other participating centers required
approval after additional marginal local IRB review to start study
Local review: Obtained primary local IRB approvals only applied to the associated research centers and allowed study start without any additional requirements
M =Missing
aIn the UK, the research protocol had to be submitted to an external national committee not associated to the submitting center. After primary approval by this
national committee, all centers required additional IRB approval
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IRBs varied. Not all IRBs considered the study to be ob-
servational, demonstrating a different way of under-
standing the study. The apparent lack of integration and
harmonization in this context suggests that the efficiency
of European research collaborations could benefit from
improving knowledge on the existing variation in proce-
dures, inefficiencies and differences in value systems be-
tween and within countries.
The duration from protocol submission to required
IRB approval was highly variable and ranged from one
day up to nearly one year. In literature, differences
between IRB procedures were also reported and IRB
review durations varied from weeks to several months
[6, 17]. The difference in total duration between primary
central and primary local IRB approval could respect-
ively be overestimated and underestimated by the short
primary IRB review times in Serbia and Romania and
the missing data of the first review round for the UK.
The difference is not necessarily related to the number
of review rounds, but might be more explained by the
reason and nature (primary central/local review or ex-
tensive/marginal additional local review) of the extra re-
view round(s), the accompanying amount of work and
the working speed of both IRB and research team. The
influence of the latter was substantiated by our data as
responding to questions from the IRB seemed to ac-
count for an important part of time in several countries
(e.g. Denmark and Norway), while the majority of time
in other countries (e.g. Belgium, Spain and France) was
accounted for by the time taken in primary evaluation
by IRBs. The exact reasons for these ‘delays’ could
however not be derived from our data and deserves fur-
ther study. They might be caused by the difficulty of re-
quirements or questions, although, according to the
communication records, IRBs mainly requested extra ex-
planation of research procedures. Based on the IRB in-
formation requests in this study, special attention should
be given to the description of inclusion criteria, in-
formed consent procedures, patient information forms,
non-standard care procedures, privacy and data security.
A quick response by investigators and agreeing on a
maximal turnover time of 1 month to 2 months for IRBs
could already minimize substantial delay. This is also in
correspondence with literature, where IRB turnover time
targets range from 30 to 60 days [17, 18].
The question whether CENTER-TBI was an observa-
tional or an interventional study did not appear to be a
clear explanation for differences in number and duration
of review rounds. Interventional studies are generally
subject to a more extensive review process, where obser-
vational study reviews may be more marginal. Nonethe-
less, duration was short in France and long in the UK.
CENTER-TBI is registered as an observational study, in
which ‘the investigator is not acting upon study
participants, but instead observing natural relationships
between factors and outcomes’ [19]. Two IRBs consid-
ered the study to be purely interventional. Interventional
studies are studies ‘where the researcher intercedes as
part of the study design’ [19]. An explanation for this
opposing classification is that the IRBs did and did not
consider the following procedures to be standard-of-
care: (1) Different amounts of additional blood draws at
presentation and follow-up. (2) Neuropsychological
assessments and outcome questionnaires up to a 24-
month follow-up. (3) Additional MRIs at sites participat-
ing in the MRI sub-study.
Extra work without clear benefits delays projects and
should be avoided when possible. An additional IRB re-
view after primary central IRB approval is usually double
work and could result in an extra delay of weeks to more
than a year, without always having clear benefits over
the already obtained primary approval [17]. Cancelling
potentially unnecessary (extensive) additional IRB review
procedures could not only reduce turnover time, but
also reduce costs. The exact costs of European IRB re-
view procedures are unfortunately unknown, but the dir-
ect costs of an IRB review and approval in the US have
been calculated to be $107.544 ($82.610 in IRB fees and
$24.934 in labor) [20].
Delays in obtaining IRB approval not only adversely
affect study initiation, but are also associated with
several other risks. Long procedures with many feedback
rounds will delay study start, frustrate researchers and
might even endanger meeting subsidiary demands.
Researchers might attempt to speed up the process by
changing the protocol or submitting the protocol to
IRBs that are considered to be less strict but able to
process the submission the quickest. This does not
necessarily serve primary research objectives and might
even hamper quality and generalizability of study results.
Optimization of IRB review procedures is urgently
needed as multinational collaborations in healthcare
research are increasing and even promoted by
multiple European research grant [4, 5, 21].
Harmonization and adequate implementation of regu-
latory and ethical standards between European coun-
tries could improve the present situation [7, 22]. The
EU already aims to freely cooperate across borders by
defining common standards and removing legal obsta-
cles, but true harmonization of Member State laws in
a research context has clearly not been established
yet [21–24]. For example, the General Data Protection
Regulation (GDPR) aimed to ensure a fair and trans-
parent processing of personal data and aimed to im-
prove patients’ control over their own data [25]. The
implementation and use of the GDPR however
showed the difficulty of harmonization in the protec-
tion of the EU citizens in this context. This was
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especially caused by the possibility for European
countries to use their own national legislation in
addition to the GDPR, which does not improve the
desired harmonization.
Harmonization remains a highly complex process
due to variation of national regulations that are based
on national customs, culture, ethics, religion and
other beliefs [6]. Harmonization of laws is designed
to incorporate different legal systems under a basic
framework. To overcome the highly complex process
of harmonization in the area of research, it has been
suggested to combine similarities between legislations
and regulations of countries under a basic framework
like a European research directive. A framework
should acknowledge these local cultural or religious
beliefs, as disregarding them is neither feasible nor
desirable. While the desirable goal of harmonizing
regulation will certainly benefit research in the future,
both IRBs and researchers will have to put in efforts
until that time. IRBs can accelerate the turnover by
only requiring central IRB approval and researchers
should respond quicker and more comprehensively to
questions from IRBs, preventing the repetition of
questions.
Strengths and limitations
The CENTER-TBI study provides a unique opportunity
to provide comprehensive insight in the procedural dif-
ferences between European IRBs. The study benefits
from its large size and because the data acquisition
process increased the quality and completeness of docu-
ments. Despite the quality of the documents, results
were still dependent on the recorded information.
Therefore, we could not always identify causal factors
for variation, which is something to look for in future
initiatives. The data on IRB review procedures in an ob-
servational study conducted with mentally incapacitated
patients in neurotrauma centers might not be
generalizable for other research settings.
Conclusions
This study shows variation between IRB procedures
across Europe, which pose major challenges to large
European research collaborations. Differences are likely
caused by the lack of harmonization, integration and im-
plementation of national legislations and regulations. To
optimize efficiency for multinational European studies in
context of obtaining IRB approval, the encountered dif-
ferences and inefficiencies should be studied further and
policymakers should evaluate the opportunities to
optimize regulatory harmonization, while acknowledging
the boundaries of national sovereignty and local cultural
preferences.
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